Prime Medicine Announces Pricing of Public Offering of Common Stock

Impact · against what's priced in

Prime Medicine's public offering of 35.7 million shares at $3.50 creates significant immediate dilution for shareholders. While the $125 million in gross proceeds extends the company's operational runway, the scale of the issuance is a negative catalyst for current share value.

PRME−0.20

No priced-in read yet

In context

The issuance of 35,714,286 shares at $3.50 per share creates immediate dilution, though it secures $125 million in capital to fund operations.

Read from the article alone

• biotech
• PRME
• capital markets
• equity raise
• genetic therapies
• public offering

Search tags